Mark T. Bunker, PharmD

LivaNova PLC (or a subsidiary), London, United Kingdom

  • 2Articles
  • 3.6KReads1
  • 2025–2026Active
  • 28Collaborators
  • 6Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Mark T. Bunker, PharmD, affiliated with LivaNova PLC in London, United Kingdom, has published research on vagus nerve stimulation (VNS) as a treatment for major depressive disorder (MDD) and its impact on suicidal ideation. His work includes studies on treatment-resistant depression and predictors of response to adjunctive VNS therapy. Bunker's articles appeared in Psychiatrist.com between 2025 and 2026, often collaborating with co-authors such as A. John Rush and Brian J. Mickey.

Publications

JCP
Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report
Original Research ▶ Video

Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report

July 8, 2026

Findings suggest that active VNS reduces suicidal ideation (SI) and potentially induces SI remission among participants with chronic TRD and baseline SI.
, , , et al
JCP
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe